๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Jinan
Clinical trial register · China

Clinical Trials in Jinan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Jinan 31 Shandong 2 Nanchang 1
Narrow the registerReset
Recruitment status
Phase
Site location
Jinan31 Shandong2 Nanchang1
All 3 locations
Target enrolment
to

Trials with a site in Jinan

31 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer
NCT07686640Local Advanced Rectal Cancer, Radiotherapy, Immunotherapy
Shandong Cancer Hospital and Institute
Phase 3
180
Jinan
2026-08-15
Not yet open
SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer
NCT07683221Pancreatic Cancer
Shandong Cancer Hospital and Institute
Phase 2
47
Jinan
2026-07-15
Recruiting
Clinical Evaluation of 177Lu-FAP-VG11 Injection in Patients With Fibroblast Activation Protein -Positive Advanced Solid Tumours
NCT07808177Fibroblast Activation Protein (FAP)-Positive Advanced Solid Tumours
Shandong Cancer Hospital and Institute
Phase EARLY_PHASE1
7
Jinan
2026-06-17
Not yet open
Concordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal Cancer
NCT07595107Rectal Cancer
Shandong Cancer Hospital and Institute
Observational
180
Jinan
2026-06-01
Recruiting
Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer
NCT07408505Advanced Pancreatic Ductal Adenocarcinoma, Cancer Anorexia-Cachexia Syndrome
Shandong Cancer Hospital and Institute
Not applicable
56
Jinan
2026-06-01
Recruiting
The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy
NCT07376174Breast Cancer, HER2/CEP17 Ratio
Shandong Cancer Hospital and Institute
Observational
300
Jinan
2026-01-10
Active, closed
A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment
NCT07669051NSCLC (Advanced Non-small Cell Lung Cancer)
Shandong Cancer Hospital and Institute
Phase 2
36
Jinan
2026-01-01
Recruiting
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
NCT07274774Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2
184
Jinan
2025-11-30
Active, closed
Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer
NCT07173387Pancreatic Cancer
Shandong Cancer Hospital and Institute
Phase 2
42
Jinan
2025-10-01
Recruiting
Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer
NCT07600268Pancreatic Cancer Non-resectable
Shandong Cancer Hospital and Institute
Phase 2
24
Jinan
2025-08-14
Recruiting
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
NCT06850090Rectal Cancer, Rectal Cancer Patients
Shandong Cancer Hospital and Institute
Phase 3
210
Jinan
2025-07-30
Recruiting
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
NCT07062055Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy
Shandong Cancer Hospital and Institute
Phase 2
54
Jinan
2025-07-25
Recruiting
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
NCT06841172OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
Shandong Cancer Hospital and Institute
Phase 3
132
Jinan
2025-07-21
Recruiting
SFRT and SCART in Radiotherapy for Bone Metastases With Soft Tissue
NCT06987370Bone Metastases in Subjects With Advanced Cancer
Shandong Cancer Hospital and Institute
Not applicable
90
Jinan
2025-06-01
Recruiting
Phase I-II Clinical Study of Taurine for External Use in the Prevention and Treatment of Acute Radiation Skin Injury
NCT06847555To Evaluate the Safety of Taurine in Preventing Acute Radiation Skin Injury Induced by Adjuvant Radiotherapy in Breast Cancer Patients
Shandong Cancer Hospital and Institute
Phase 1/2
24
Jinan
2025-05-25
Recruiting
Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma
NCT06980259Soft Tissue Sarcoma (STS)
Shandong Cancer Hospital and Institute
Not applicable
106
Jinan
2025-05-20
Recruiting
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
NCT06802757Breast Cancer
Shandong Cancer Hospital and Institute
Phase 2
72
Jinan
2025-05-01
Recruiting
Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)
NCT07026422Rectal Malignant Neoplasms
Shandong Cancer Hospital and Institute
Phase 2
54
Jinan
2025-04-30
Recruiting
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
NCT06942416Cervical Cancer, Neoplasm Recurrence, Local, Oligometastatic
Shandong Cancer Hospital and Institute
Phase 2
36
Jinan
2025-02-28
Recruiting
Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
NCT06844422Pancreatic Cancer
Shandong Cancer Hospital and Institute
Phase 1/2
37
Jinan
2025-02-08
Recruiting
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
NCT06816771Rhabdomyosarcoma, Recurrent, Refractory
Shandong Cancer Hospital and Institute
Phase 2
38
Jinan
2025-02
Not yet open
A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
NCT06649448Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF
Shandong Cancer Hospital and Institute
Not applicable
200
Jinan
2024-10-10
Recruiting
Early Screening Cohort Study of Multiple Gastrointestinal Tumors
NCT07106424Early Detection of Cancer
Shandong Cancer Hospital and Institute
Observational
4,000
Jinan
2024-09-10
Recruiting
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
NCT06778382Colorectal Neoplasms Malignant
Shandong Cancer Hospital and Institute
Phase 2
22
Jinan
2024-06-24
Recruiting
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
NCT06532539Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
Shandong Cancer Hospital and Institute
Phase 2
30
Jinan
2024-06-13
Recruiting
Fruquintinib Combined With Sintilimab ยฑ Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
NCT06356584Colorectal Cancer, Immunotherapy, Radiotherapy, Targeted Therapy
Shandong Cancer Hospital and Institute
Phase 2
62
Jinan
2024-04-01
Active, closed
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
NCT06246344Rectal Cancer
Shandong Cancer Hospital and Institute
Phase 3
128
Jinan
2023-12-01
Recruiting
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
NCT06050317Pancreas Cancer
Shandong Cancer Hospital and Institute
Phase 2
25
Jinan
2023-08-18
Recruiting
A Study of Orelabrutinib Plus R-CHOP in Treatment-naรฏve Patients With Double Expression Diffuse Large B-cell Lymphoma
NCT05933967The First Affiliated Hospital of Nanchang University
Shandong Cancer Hospital and Institute
Phase 2
31
Nanchang, Jinan
2023-06-01
Recruiting
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
NCT06241807IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma, Biomarkers / Blood
Shandong Cancer Hospital and Institute
Phase 2
30
Jinan
2022-12-02
Recruiting
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy
NCT04829708Limited Stage Small Cell Lung Cancer
Shandong Cancer Hospital and Institute
Phase 3
534
Jinan
2021-04-26
Rows per page Showing 1–31 of 31
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/jinan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 31 of those studies with a site in Jinan that also match the filters currently applied.

How many clinical trials are recruiting in Jinan?

25 of the 31 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Jinan), 31 studies
PhaseStudiesRecruitingShare
Phase 2161351.6%
Phase 35416.1%
Not applicable4312.9%
Observational329.7%
Phase 1/2226.5%
Phase EARLY_PHASE1113.2%

Most active sponsors

Lead sponsors with the most studies (Jinan)
Lead sponsorStudiesRecruiting
Shandong Cancer Hospital and Institute3125
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.